Usefulness of Plasma SARS-CoV-2 RNA Quantification by Droplet-based Digital PCR to Monitor Treatment Against COVID-19 in a B-cell Lymphoma Patient.

Published on Jan 5, 2021in Stem Cell Reviews and Reports5.316
· DOI :10.1007/S12015-020-10107-5
Tali Anne Szwebel4
Estimated H-index: 4
David Veyer12
Estimated H-index: 12
(University of Paris)
+ 17 AuthorsHélène Péré6
Estimated H-index: 6
(University of Paris)
We report the case of an HIV-1-infected patient, treated with anti-CD20 monoclonal antibody for a B-cell lymphoma previously treated by autologous stem cell transplant. He suffered from chronic COVID19 and we monitored by plasma SARS-CoV-2 RNA by highly sensitive droplet-based digital PCR technology (ddPCR). Under tocilizumab therapy and despite a first clinical improvement biologically associated with decreasing inflammatory markers, a slight increase of SARS-CoV-2 RNAaemia quantified by ddPCR was highlighted, confirming the absence of viral efficacy of this treatment and predicting the subsequent observed deterioration. As expected, his complete recovery, finally achieved after COVID-19 convalescent plasmatherapy, strictly paralleled plasma SARS-CoV-2 RNA clearance. With these results, we confirmed the interest of SARS-CoV-2 RNAaemia monitoring by ddPCR in COVID-19 patients, particularly during treatment, and firstly showed that this new and specific biomarker could be helpful to select eligible patient for anti-IL6 receptors therapy considering the variable levels of efficacy recently observed with such therapy.
📖 Papers frequently viewed together
3 Citations
5 Citations
22 Authors (Sudeb C. Dalai, ..., Lance Baldo)
3 Citations
#1Coralie L. Guerin (University of Paris)H-Index: 3
#1Coralie L Guerin (University of Paris)H-Index: 24
Last. David M. Smadja (University of Paris)H-Index: 30
view all 26 authors...
Endothelial progenitor cells (EPCs) are involved in vasculogenesis and cardiovascular diseases. However, the phenotype of circulating EPCs remains elusive but they are more often described as CD34+KDR+. The aim of the study was to extensively characterize circulating potential vasculogenic stem cell candidates in two populations of patients with cardiovascular disease by powerful multidimensional single cell complementary cytometric approaches (mass, imaging and flow). We identified cellular can...
4 CitationsSource
#1Jérôme Avouac (University of Paris)H-Index: 60
#2Paolo AiròH-Index: 59
Last. Yannick Allanore (University of Paris)H-Index: 81
view all 5 authors...
The case reported by Guilpain et al attracted our attention. This case of granulomatosis with polyangiitis on immunosuppressants, including recent maintenance therapy with rituximab (RTX), developed a severe and life-threatening coronavirus-2 (SARS-CoV-2) disease 2019 (COVID-19). The particularity of this observation was the occurrence of a more progressive worsening than observed in most series.1 Herein, we report the observation of three patients with systemic sclerosis (SSc) routinely treated...
40 CitationsSource
#1Benjamin Debuc (University of Paris)H-Index: 5
#2David M. Smadja (French Institute of Health and Medical Research)H-Index: 30
Last. David Smadja (French Institute of Health and Medical Research)H-Index: 1
view all 2 authors...
SARS-CoV-2 viruses are positive single-stranded RNA viruses, whose infection can be asymptomatic or lead to the coronavirus disease 2019 (Covid-19). Covid-19 is a respiratory infection with a significant impact on the hematopoietic system and hemostasis leading to several cardiovascular complications. Hematologic consequences of this new infection allowed medical community to start new treatment approaches concerning infection going from targeted anti-inflammatory drugs to anticoagulation or ste...
37 CitationsSource
#1Jonathan B. Parr (UNC: University of North Carolina at Chapel Hill)H-Index: 14
51 CitationsSource
#1Thomas Hueso (Université Paris-Saclay)H-Index: 3
#1Thomas HuesoH-Index: 4
Last. Karine Lacombe (University of Paris)H-Index: 32
view all 36 authors...
Anti-CD20 monoclonal antibodies are widely used for the treatment of hematological malignancies or autoimmune disease but may be responsible for a secondary humoral deficiency. In the context of COVID-19 infection, this may prevent the elicitation of a specific SARS-CoV-2 antibody response. We report a series of 17 consecutive patients with profound B-cell lymphopenia and prolonged COVID-19 symptoms, negative immunoglobulin G (IgG)-IgM SARS-CoV-2 serology, and positive RNAemia measured by digita...
75 CitationsSource
#1David Veyer (University of Paris)H-Index: 12
#1David Veyer (University of Paris)H-Index: 7
Last. Hélène Péré (University of Paris)H-Index: 20
view all 13 authors...
BACKGROUND: Coronavirus disease 2019 (COVID-19) is a global public health problem that has already caused more than 662,000 deaths worldwide. Although the clinical manifestations of COVID-19 are dominated by respiratory symptoms, some patients present other severe damage such as cardiovascular, renal and liver injury or/and multiple organ failure, suggesting a spread of the SARS-CoV-2 in blood. Recent ultrasensitive polymerase chain reaction (PCR) technology now allows absolute quantification of...
45 CitationsSource
Cited By4
#1David M. Smadja (University of Paris)H-Index: 30
#2Steven J. Mentzer (Brigham and Women's Hospital)H-Index: 66
Last. Nicolas Gendron (University of Paris)H-Index: 11
view all 24 authors...
1 CitationsSource
#1Jonathon W. Senefeld (Mayo Clinic)H-Index: 14
#2Stephen A. Klassen (Mayo Clinic)H-Index: 8
Last. Michael J. Joyner (Mayo Clinic)H-Index: 93
view all 20 authors...
In the absence of effective countermeasures, human convalescent plasma has been widely used to treat severe acute respiratory syndrome coronavirus 2, the causative agent of novel coronavirus disease 19 (COVID-19), including among patients with innate or acquired immunosuppression. However, the association between COVID-19-associated mortality in patients with immunosuppression and therapeutic use of convalescent plasma is unknown. We review 75 reports, including one large matched-control registr...
2 CitationsSource
#1Stephen A. Klassen (Mayo Clinic)H-Index: 8
#2Jonathon W. Senefeld (Mayo Clinic)H-Index: 14
Last. Eric Salazar (Cornell University)H-Index: 14
view all 23 authors...
To determine the effect of COVID-19 convalescent plasma on mortality, we aggregated patient outcome data from 10 randomized clinical trials, 20 matched control studies, 2 dose-response studies, and 96 case reports or case series. Studies published between January 1, 2020, and January 16, 2021, were identified through a systematic search of online PubMed and MEDLINE databases. Random effects analyses of randomized clinical trials and matched control data demonstrated that patients with COVID-19 t...
15 CitationsSource
SUMMARY Patients lacking humoral response have been suggested to develop a less severe COVID-19, but there are some reports with a prolonged, relapsing or deadly course. From April 2020, there is growing evidence on the benefits of COVID-19 convalescent plasma (CCP) for patients with humoral immunodeficiency. Most of them had a congenital primary immunodeficiency or were on treatment with anti CD20 antibodies. We report on three patients treated in our hospital and review thirty-one more cases d...
2 CitationsSource